相关实验视频
Updated: May 21, 2025
08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
940
阿瓦科潘作为一种类固醇节约疗法,用于复发性多炎的粒状瘤病
Nisha Sapkota1, Yubraj Aryal2, Prasansa Basnet3
1Medicine, One Brooklyn Health-Interfaith Medical Center, New York, USA.
Cureus
|March 20, 2025
概括
带有多胞膜炎 (GPA) 的颗粒瘤病是一种罕见的自身免疫性疾病. 一种新的药物,阿瓦科潘,通过减少类固醇依赖和炎症来管理复发性GPA.
科学领域:
- 类风湿病学 类风湿病学
- 免疫学 免疫学 免疫学
- 腎臟病學 (nephrology) 是一種醫學專業.
背景情况:
- 带有多管炎 (GPA) 的粒状瘤炎是一种罕见的全身性自身免疫性血管炎,影响小至中型血管.
- GPA通常会影响呼吸道 (肺,鼻) 和脏,导致严重的器官损伤.
- 管理通常涉及免疫抑制药物,通常包括皮质类固醇,这些药物具有显著的长期副作用.
研究的目的:
- 报告一个复发性多质炎 (GPA) 颗粒瘤病例.
- 评估阿瓦科潘在耐火性GPA患者中的疗效和类固醇节约潜力.
- 突出阿瓦科班在管理GPA爆发和减少长期皮质类固醇暴露中的作用.
主要方法:
- 一个66岁的男性病例报告,有复发性GPA的病史.
- 治疗方案包括高剂量普得尼松,利图西马布和阿瓦科班 (一种C5a受体抑制剂).
- 监测了临床反应,炎症标志物和减少皮质类固醇的需要.
主要成果:
- 患者经历了症状的快速改善,包括鼻塞,表和肺结节的解脱.
- 阿瓦科潘有助于显著降低普得尼松剂量,显示出强大的抗炎作用.
- 组合疗法导致GPA爆发的成功管理,降低了类固醇负担.
结论:
- 阿瓦科潘显示承诺作为一个有效的类固醇节约剂在管理的花质瘤与多炎.
- 这一案例支持使用阿瓦科班来控制GPA活性,并减轻长期皮质类固醇相关的不良影响.
- 准C5a受体通路代表了对像GPA这样的自身免疫血管类药物有价值的治疗策略.
相关概念视频
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
123
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
123
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
140
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
140
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
92
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
92
01:29Drugs for Treatment of Ulcerative Colitis in IBD
114
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
114
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
356
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
356
01:29Inflammatory Bowel Disease IV: Pharmacological Management
83
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
83